Medical Condition News

RSS

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Ikaria, Inc. today announced that the U.S. Food and Drug Administration has granted INOMAX for inhalation an additional six months of marketing exclusivity, known as "pediatric exclusivity."

6 Jan 2011

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

The University of Texas Health Science Center at Houston has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child's own umbilical cord blood stem cells for traumatic brain injury in children.

6 Jan 2011

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Maternal depression adversely affects quality of life in children with epilepsy

A study by Canadian researchers examined the prevalence of maternal depression and its impact on children newly diagnosed with epilepsy. Prevalence of depression in mothers ranged from 30%-38% within the first 24 months following a child’s epilepsy diagnosis. The mother’s depressive symptoms negatively impacted the child’s health-related quality of life, but the effects were moderated by the amount of family resources and mediated by how well the family functions and the extent of family demands. Details of this novel study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

5 Jan 2011

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

Bright light therapy for the aged depressed: Study

A new study shows that exposure to bright light may ease symptoms of depression in elderly people. The researchers tried three weeks of bright light therapy using specially designed light boxes and saw that it improved symptoms of depression by as much as 54% in older adults with depression. The light therapy also improved sleep and optimized levels of the neurotransmitter serotonin. Low levels of serotonin are associated with depression and often targeted by antidepressant drugs. This is the first study of its kind to show a beneficial effect of bright light therapy on treating depression in the elderly with non-seasonal major depressive disorder.

5 Jan 2011

Spectrum Pharmaceuticals enters agreement with Viropro to develop biosimilar rituximab

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has signed a letter of agreement with Viropro, Inc., for the development of a biosimilar version of the monoclonal antibody drug rituximab (marketed by Genentech/Roche). Worldwide sales of rituximab in 2009 in all indications, including non-Hodgkin's lymphoma and chronic lymphocytic lymphoma, were approximately $5.6 billion.

5 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

5 Jan 2011

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

Alfred O. Bonati, M.D., internationally known orthopedic surgeon and founder of The Bonati Spine Institute, reports that, in his experience, the failure rates for open back surgery, as recently reported by the Ohio Bureau of Workers' Compensation, are not out of line.

5 Jan 2011

American Heart Association partners in global effort to prepare for UN non-communicable diseases summit

The American Heart Association is participating in an international effort to prepare for a United Nations (UN) high-level summit next year on non-communicable diseases (NCDs). These diseases — mainly cardiovascular illnesses including stroke, diabetes, cancer and chronic respiratory conditions — were estimated to cause more than 60 percent of deaths worldwide in 2005.

5 Jan 2011

Soldiers with positive outlook in traumatic situations less likely to suffer anxiety, depression

In the first combat-zone study of its kind, a research team led by Michigan State University found that soldiers with a positive outlook in the most traumatic situations were less likely to suffer health problems such as anxiety and depression.

5 Jan 2011

Neuroscientist says spatial strategies can reduce risk of dementia

Véronique Bohbot, PhD., neuroscientist at the Douglas Mental Health University Institute and associate professor at McGill University, leads studies on navigational strategies. She presented her findings at the recent meeting of the Society for Neuroscience in San Diego, which could bring light into how we can make better use of our hippocampus in order to reduce the risk of dementia.

5 Jan 2011

Predictive value of plasma galectin-3 levels in heart failure patients: Study

BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.

5 Jan 2011

Study shows adolescents who were breastfed at birth have stronger leg muscles

Breast feeding new born babies has lots of advantages in the short and in the long-term for babies. A study has confirmed the recently discovered benefits, which had not been researched until now. Adolescents who are breast fed at birth have stronger leg muscles than those who received artificial milk.

5 Jan 2011

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.

5 Jan 2011

KINAXO, AstraZeneca enter oncology research collaboration

KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca's oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale.

5 Jan 2011

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

A study that included more than 100,000 patients who received implantable cardioverter-defibrillators (ICDs) found that about 20 percent did not meet evidence-based guidelines for receipt of an ICD, and that these patients had a significantly higher risk of in-hospital death than individuals who met criteria for receiving an ICD, according to a study in the January 5 issue of JAMA.

5 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

Medical Condition News

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

Maternal depression adversely affects quality of life in children with epilepsy

EDMA to endorse the campaign on Hypoparathyroidism

Bright light therapy for the aged depressed: Study

Spectrum Pharmaceuticals enters agreement with Viropro to develop biosimilar rituximab

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

American Heart Association partners in global effort to prepare for UN non-communicable diseases summit

Soldiers with positive outlook in traumatic situations less likely to suffer anxiety, depression

Neuroscientist says spatial strategies can reduce risk of dementia

Predictive value of plasma galectin-3 levels in heart failure patients: Study

Study shows adolescents who were breastfed at birth have stronger leg muscles

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

KINAXO, AstraZeneca enter oncology research collaboration

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

EUSA receives FDA Priority Review status for ERWINAZE BLA

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News